New Ovarian Cancer Trial Results Will Be Presented
New findings for a dual-drug therapy in low-grade serous ovarian cancer will be shared at a global conference in October.
Updated on Sept. 24, 2026 in Cancer
Live Poll
Do you trust that clinical trial data reliably proves the benefits of new cancer medications?
Verastem Oncology will present Phase 2 clinical trial data for the treatment of recurrent low-grade serous ovarian cancer (LGSOC) at the IGCS 2026 Annual Global Meeting. These findings, scheduled for presentation on October 2, 2026, include new tumor biomarker analysis and data from international study cohorts.
Why it matters
Low-grade serous ovarian cancer, which affects an estimated 80,000 women worldwide, has historically been challenging to treat due to tumor resistance. This data presentation offers insight into a therapy combination that aims to improve outcomes for patients with this specific malignancy.
The RAMP 201 Phase 2 clinical trial utilizes a randomized, open-label design to evaluate the combination of avutometinib and defactinib in patients with recurrent LGSOC. Results shared at the meeting will highlight molecular profiling and tumor biomarker analysis from the study.
The players
Verastem Oncology
A biopharmaceutical company focused on developing targeted treatments for cancer, specifically those involving the MAPK pathway.
Susana N. Banerjee
A medical oncologist specializing in ovarian cancer research and clinical trial development.
Shogo Shigeta
A clinical researcher focused on gynecologic oncology and patient outcomes in Japanese study cohorts.
Rachel Grisham
A clinical expert in the evaluation of cancer therapies and external control arm data analysis.
The details
The treatment combines avutometinib and defactinib to create a more complete blockade of the RAS/MAPK signaling pathway. By simultaneously targeting this pathway, the therapy aims to overcome the mechanisms that drive tumor growth and drug resistance in patients whose cancer cells harbor specific mutations.
Timeline
The IGCS Annual Global Meeting takes place from October 1 to October 3, 2026.
Presentations for RAMP 201 and RAMP 201J occur on October 2, 2026, at 10:30 a.m. ET.
An external control arm analysis will be presented on October 2, 2026, at 2:25 p.m. ET.
Health Landscape
This presentation builds on the current standard of care established by the FDA's 2025 approval of the AVMAPKI FAKZYNJA CO-PACK. It aligns with the broader research effort to confirm the long-term clinical benefits of combination therapy in the RAMP 301 Phase 3 trial.
For patients living with low-grade serous ovarian cancer, these findings may clarify the role of molecular and biomarker testing in choosing a treatment path. Discuss with your physician whether your specific tumor profile makes these targeted therapies a relevant topic for your care plan.
The takeaway
Combination therapies are increasingly being tested to overcome tumor resistance in rare cancers like LGSOC. Patients and caregivers should track the progress of ongoing confirmatory trials to understand how these developments may shift the standard of care.
Further reading
Learn more about the latest research and treatment advancements in Cancer.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that clinical trial data reliably proves the benefits of new cancer medications?
